DailyMed: Egrifta WR prescribing information
Source of approved indication scope for tesamorelin in HIV-associated lipodystrophy.
Evidence memo
Tesamorelin
Also tracked as: Egrifta WR, Egrifta SV
An approved medicine for a specific HIV-associated lipodystrophy context, often overgeneralized into broader body-composition claims.
Approved specific use Approved specific use
Evidence status
Clinically established in specific contexts. Evidence level: Approved specific use.
Claim being evaluated
Where tesamorelin's approved evidence boundary ends and broader wellness or physique claims begin.
Why people care
It is one of the few peptide-related medicines with an FDA-approved use, which makes it easy for online claims to stretch the context.
Signal so far
Evidence is strongest for the approved HIV-associated lipodystrophy indication.
Biggest unknown
Whether off-label body-composition narratives have clinically meaningful outcome evidence in different populations.
Safety/regulatory boundary
Approved specific use does not equal general wellness proof.
Watch next
Label changes, post-market safety, and any controlled trials in clearly defined non-label populations.
Evidence interpretation
Established, but only in a narrow clinical context.